Analyzing Stock On Your Own: Phio Pharmaceuticals Corp (NASDAQ: PHIO)

Phio Pharmaceuticals Corp (NASDAQ:PHIO) does about 162.16K shares in volume on a normal day but saw 11106037 shares change hands in the recent trading day. The company now has a market cap of 2.38M USD. Its current market price is $2.23, marking an increase of 26.70% compared to the previous close of $1.76. The 52 week high reached by this stock is $10.35 whilst the lowest price level in 52 weeks is $1.53.

Phio Pharmaceuticals Corp (PHIO) has a 20-day trading average at $2.6200 and the current price is -78.45% off the 52-week high compared with 45.75% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.7500 and its 200-day simple moving average is $4.5800. If we look at the stock’s price movements over the week, volatility stands at 38.35%, which decreases to 14.98% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 42.62 to suggest the stock is neutral.

The consensus objective for the share price is $36.00, suggesting that the stock has a potential upside of 93.81% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 05, 2020 when H.C. Wainwright initiated the stock to “Buy” and issued a price target of $4.

The current price level is -14.75%, -18.81%, and -51.36% away from its SMA20, SMA50, and SMA200 respectively, with the PHIO price moving above the 50-day SMA on current market day. Phio Pharmaceuticals Corp (PHIO) stock is down -21.48% over the week and -11.86% over the past month. Its price is -67.40% year-to-date and -67.77% over the past year.

The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.

To reach the target analysts have set, the stock logically needs to grow 93.81 percent from here.

Outstanding shares total 1.06M with insiders holding 4.81% of the shares and institutional holders owning 3.02% of the company’s common stock. The company has a return on investment of -150.00% and return on equity of -122.03%. The beta has a value of 1.50. Price to book ratio is 0.43.